Armata Pharmaceuticals – BioScience Managers

Armata Pharmaceuticals Announces $15 Million Award from the U.S. Department of Defense (DoD) for Development of Bacteriophage Therapy to Treat S. aureus Bacteremia Infections

17th June 2020/in Armata Pharmaceuticals

Link to Full Article Non-dilutive funding to be used to advance the company’s second phage-based therapeutic candidate in a Phase 1b/2 clinical study MARINA DEL REY, Calif., June 17, 2020 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant and difficult-to-treat bacterial infections, today […]

Armata Pharmaceuticals Announces First Quarter 2020 Results and Provides General Corporate Update

14th May 2020/in Armata Pharmaceuticals

Link to Full Article MARINA DEL REY, Calif., May 14, 2020 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced results for the first quarter of 2020 and provided a corporate and clinical update. Key First Quarter 2020 and Subsequent […]

Armata Pharmaceuticals Announces Closing of Second Tranche of $25 Million Securities Purchase Agreement with Innoviva, Inc.

30th March 2020/in Armata Pharmaceuticals

Link to Full Article – Funds to be used primarily to advance its lead Pseudomonas aeruginosa candidate, AP-PA02 MARINA DEL REY, Calif., March 30, 2020 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that, following a vote in favor […]

Armata Pharmaceuticals Announces Fourth Quarter and Full Year 2019 Results and Provides General Corporate Update

19th March 2020/in Armata Pharmaceuticals

Link to Full Article MARINA DEL REY, Calif., March 19, 2020 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced results for the fourth quarter and full year 2019 and provided a corporate and clinical update. Key Fourth Quarter and […]

Armata Pharmaceuticals Announces up to $5 Million Therapeutics Development Award from the Cystic Fibrosis Foundation

18th March 2020/in Armata Pharmaceuticals

Link to Full Article Award to help fund a Phase 1/2 clinical trial of the company’s Pseudomonas aeruginosa phage candidate, AP-PA02, as a treatment for drug-resistant respiratory infections in cystic fibrosis patients Armata to collaborate with the Cystic Fibrosis Therapeutics Development Network MARINA DEL REY, Calif., March 18, 2020 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) […]

Armata Pharmaceuticals Announces Closing of First Tranche of Recently Executed $25 Million Securities Purchase Agreement with Innoviva, Inc.

13th February 2020/in Armata Pharmaceuticals

Link to Full Article – Armata withdraws its previously filed registration statement on Form S-1 MARINA DEL REY, Calif., Feb. 13, 2020 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that it has completed the first closing under a recently […]

Armata Pharmaceuticals and Innoviva Announce $25 Million Strategic Investment to Support Advancement of Armata’s Bacteriophage Development Programs

28th January 2020/in Armata Pharmaceuticals

Link to Full Article MARINA DEL REY, Calif. and BRISBANE, Calif., Jan. 28, 2020 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata”), a biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, and Innoviva, Inc. (NASDAQ: INVA) (“Innoviva”), a company with a portfolio of royalties that include respiratory assets partnered with Glaxo Group Limited, today announced that […]

Armata Pharmaceuticals Announces Third Quarter Results and Provides Corporate and Clinical Update

12th November 2019/in Armata Pharmaceuticals

Link to Full Article MARINA DEL REY, Calif., Nov. 12, 2019 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced third quarter results and provided a corporate and clinical update. Key Third Quarter and Subsequent Period Highlights: Announced development of […]

Armata Pharmaceuticals Announces Receipt of $1.3 million R&D Tax Incentive

21st October 2019/in Armata Pharmaceuticals

Link to Full Article MARINA DEL REY, Calif., Oct. 21, 2019 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata”), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that it has received a Research and Development (R&D) Tax Incentive cash rebate of USD $1.3 million from the Australian Tax Office based on Armata’s […]

Armata Pharmaceuticals Announces Development of New Synthetic Phage Candidate Targeting Pseudomonas aeruginosa

12th September 2019/in Armata Pharmaceuticals

Link to Full Article Initial clinical emphasis on difficult-to-treat respiratory infections in cystic fibrosis patients MARINA DEL REY, Calif., Sept. 12, 2019 /PRNewswire/ — Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (the “Company” or “Armata”), a clinical-stage biotechnology company focused on precisely targeted bacteriophage therapeutics for antibiotic-resistant infections, today announced that the Company has developed a new synthetic phage […]